skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Elsevier ClinicalKey Journals remover idioma: Russo remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Fuchs, Charles S, Dr Prof ; Tomasek, Jiri, MD ; Yong, Cho Jae, Prof ; Dumitru, Filip, MD ; Passalacqua, Rodolfo, MD ; Goswami, Chanchal, Prof ; Safran, Howard, Prof ; dos Santos, Lucas Vieira, MD ; Aprile, Giuseppe, MD ; Ferry, David R, Prof ; Melichar, Bohuslav, Prof ; Tehfe, Mustapha, MD ; Topuzov, Eldar, Prof ; Zalcberg, John Raymond, Prof ; Chau, Ian, MD ; Campbell, William, Prof ; Sivanandan, Choondal, MD ; Pikiel, Joanna, MD ; Koshiji, Minori, MD ; Hsu, Yanzhi, PhD ; Liepa, Astra M, PharmD ; Gao, Ling, PhD ; Schwartz, Jonathan D, MD ; Tabernero, Josep, MD

The Lancet (British edition), 2014-01, Vol.383 (9911), p.31-39 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
2
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Dalton, Tracy, Dr ; Cegielski, Peter, MD ; Akksilp, Somsak, MD ; Asencios, Luis, MPH ; Caoili, Janice Campos, MD ; Cho, Sang-Nae, Prof ; Erokhin, Vladislav V, MD ; Ershova, Julia, PhD ; Gler, Ma Tarcela, MD ; Kazennyy, Boris Y, MD ; Kim, Hee Jin, MD ; Kliiman, Kai, MD ; Kurbatova, Ekaterina, MD ; Kvasnovsky, Charlotte, MD ; Leimane, Vaira, MD ; van der Walt, Martie, PhD ; Via, Laura E, PhD ; Volchenkov, Grigory V, MD ; Yagui, Martin A, MD ; Kang, Hyungseok, MD

The Lancet (British edition), 2012-10, Vol.380 (9851), p.1406-1417 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

Franz, David Neal, Prof ; Belousova, Elena, MD ; Sparagana, Steven, MD ; Bebin, E Martina, MD ; Frost, Michael, MD ; Kuperman, Rachel, MD ; Witt, Olaf, MD ; Kohrman, Michael H, MD ; Flamini, J Robert, MD ; Wu, Joyce Y, MD ; Curatolo, Paolo, Prof ; de Vries, Petrus J, Prof ; Whittemore, Vicky H, PhD ; Thiele, Elizabeth A, MD ; Ford, James P, MS ; Shah, Gaurav, MD ; Cauwel, Helene, MSc ; Lebwohl, David, MD ; Sahmoud, Tarek, MD ; Jozwiak, Sergiusz, MD

The Lancet (British edition), 2013-01, Vol.381 (9861), p.125-132 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
4
A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma
Material Type:
Artigo 		Adicionar ao Meu Espaço

A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma

Van Poppel, Hendrik ; Da Pozzo, Luigi ; Albrecht, Walter ; Matveev, Vsevolod ; Bono, Aldo ; Borkowski, Andrzej ; Colombel, Marc ; Klotz, Laurence ; Skinner, Eila ; Keane, Thomas ; Marreaud, Sandrine ; Collette, Sandra ; Sylvester, Richard

European urology, 2011-04, Vol.59 (4), p.543-552 [Periódico revisado por pares]

Kidlington: Elsevier B.V

Texto completo disponível

Citações Citado por
5
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

van Lunzen, Jan, Prof ; Maggiolo, Franco, MD ; Arribas, José R, Prof ; Rakhmanova, Aza, MD ; Yeni, Patrick, Prof ; Young, Benjamin, MD ; Rockstroh, Jürgen K, Prof ; Almond, Steve, MMath ; Song, Ivy, PhD ; Brothers, Cindy, MSPH ; Min, Sherene, MD

The Lancet infectious diseases, 2012-02, Vol.12 (2), p.111-118 [Periódico revisado por pares]

London: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial

Bussel, James B, MD ; Provan, Drew, MD ; Shamsi, Tahir, MD ; Cheng, Gregory, MD ; Psaila, Bethan, MD ; Kovaleva, Lidia, MD ; Salama, Abdulgabar, MD ; Jenkins, Julian M, MSc ; Roychowdhury, Debasish, MD ; Mayer, Bhabita, MSc ; Stone, Nicole, PhD ; Arning, Michael, MD

The Lancet (British edition), 2009-02, Vol.373 (9664), p.641-648 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
7
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled study

Hough, David ; Gopal, Srihari ; Vijapurkar, Ujjwala ; Lim, Pilar ; Morozova, Margarita ; Eerdekens, Mariëlle

Schizophrenia research, 2010-02, Vol.116 (2), p.107-117 [Periódico revisado por pares]

Amsterdam: Elsevier B.V

Texto completo disponível

Citações Citado por
8
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Bissler, John J, Prof ; Kingswood, J Christopher, FRCP ; Radzikowska, Elżbieta, MD ; Zonnenberg, Bernard A, MD ; Frost, Michael, MD ; Belousova, Elena, Prof ; Sauter, Matthias, MD ; Nonomura, Norio, Prof ; Brakemeier, Susanne, MD ; de Vries, Petrus J, Prof ; Whittemore, Vicky H, PhD ; Chen, David, PhD ; Sahmoud, Tarek, MD ; Shah, Gaurav, MD ; Lincy, Jeremie, MS ; Lebwohl, David, MD ; Budde, Klemens, Prof

The Lancet (British edition), 2013-03, Vol.381 (9869), p.817-824 [Periódico revisado por pares]

Kidlington: Elsevier

Texto completo disponível

Citações Citado por
9
Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial
Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Autonomic Denervation Added to Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial

KATRITSIS, Demosthenes G ; POKUSHALOV, Evgeny ; ROMANOV, Alexander ; GIAZITZOGLOU, Eleftherios ; SIONTIS, George C. M ; PO, Sunny S ; CAMM, A. John ; IOANNIDIS, John P. A

Journal of the American College of Cardiology, 2013-12, Vol.62 (24), p.2318-2325 [Periódico revisado por pares]

New York, NY: Elsevier

Texto completo disponível

Citações Citado por
10
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

Jacobson, Ira M, Prof ; Dore, Gregory J, Prof ; Foster, Graham R, Prof ; Fried, Michael W, Prof ; Radu, Monica, MD ; Rafalsky, Vladimir V, Prof ; Moroz, Larysa, Prof ; Craxi, Antonio, Prof ; Peeters, Monika, MSc ; Lenz, Oliver, PhD ; Ouwerkerk-Mahadevan, Sivi, PhD ; De La Rosa, Guy, MD ; Kalmeijer, Ronald, MD ; Scott, Jane, PhD ; Sinha, Rekha, PhD ; Beumont-Mauviel, Maria, PhD

The Lancet (British edition), 2014-08, Vol.384 (9941), p.403-413 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Revistas revisadas por pares (132)

Data de Publicação 

De até
Refinar
  1. Antes de1996  (11)
  2. 1996Até1999  (11)
  3. 2000Até2003  (19)
  4. 2004Até2008  (42)
  5. Após 2008  (51)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (132)
  2. Japonês  (17)
  3. Francês  (1)
  4. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.